Home Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry
Article
Licensed
Unlicensed Requires Authentication

Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry

  • Per Magne Ueland , Øivind Midttun , Amrei Windelberg , Asbjørn Svardal , Rita Skålevik and Steinar Hustad
Published/Copyright: December 8, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 12

Abstract

Background: Derangements of one-carbon metabolism have been related to the development of chronic diseases. Metabolic profiling as part of epidemiological studies in this area should include intermediates involved in the transfer of one-carbon units, cofactors for the relevant enzymes and markers of inflammation, kidney function and smoking.

Methods: We established five platforms that measured 6–16 analytes each. Platforms A (gas chromatography-mass spectrometry; GC-MS) and B (gas chromatography-tandem mass spectrometry; GC-MS/MS) involved methylchloroformate derivatization of primary amines, thiols and carboxylic acids. Platform C determined basic compounds by liquid chromatography-tandem mass spectrometry (LC-MS/MS), using an ether-linked phenyl reversed-phase column. Platforms D and E (LC-MS/MS) exploited the efficient ionization and high sensitivity obtained for a wide range of analytes, using a mobile phase containing a high concentration of acetic acid. The chromatographic run times ranged from 3 to 8 min.

Results: The analyte concentrations ranged from 0.2 nmol/L to 400 μmol/L. Platforms A and B both measured methylmalonic acid, total homocysteine and related amino acids. Platform B also included sarcosine, cystathionine, tryptophan and kynurenine. Platform C was optimized for the measurement of choline and betaine, but also included arginine, asymmetric and symmetric dimethylarginine and creatinine. A diversity of low abundance compounds mainly occurring in the nanomolar range were measured on platform D. These were vitamin B2 and B6 species, neopterin, cotinine and tryptophan metabolites. Platform E measured folates and folate catabolites.

Conclusions: Approximately 40 analytes related to one-carbon metabolism were determined in less than 1 mL of plasma/serum using five complementary analytical platforms. As a method control, several metabolites were measured on two or more platforms. Logistics and data handling were carried out by specially designed software. This strategy allows profiling of one-carbon metabolism in large-scale epidemiological studies.

Clin Chem Lab Med 2007;45:1737–45.


Corresponding author: Dr. Per Magne Ueland, Section for Pharmacology, Institute of Medicine, University of Bergen, 5021 Bergen, Norway Phone: +47-55973147, Fax: +47-55974605,

Received: 2007-6-17
Accepted: 2007-9-4
Published Online: 2007-12-08
Published in Print: 2007-12-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Homocysteine research: alive and kicking!
  2. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis
  3. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial
  4. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients
  5. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases
  6. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
  7. Biomarkers of folate and vitamin B12 status in cerebrospinal fluid
  8. The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis – a systematic review
  9. Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review
  10. Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?
  11. Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease
  12. Hyperhomocysteinemia, DNA methylation and vascular disease
  13. Measuring subclinical atherosclerosis: is homocysteine relevant?
  14. Plasma protein homocysteinylation in uremia
  15. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease
  16. Hyperhomocysteinemia – association with renal transsulfuration and redox signaling in rats
  17. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine
  18. Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias
  19. The molecular basis of homocysteine thiolactone-mediated vascular disease
  20. Importance of folate-homocysteine homeostasis during early embryonic development
  21. Association between homocysteine, vitamin B6 concentrations and inflammation
  22. Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry
  23. Holotranscobalamin in laboratory diagnosis of cobalamin deficiency compared to total cobalamin and methylmalonic acid
  24. Haptocorrin in humans
  25. Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase
  26. Decreased p66Shc promoter methylation in patients with end-stage renal disease
  27. Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling
  28. Differential expression of γ-aminobutyric acid receptor A (GABAA) and effects of homocysteine
  29. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial
  30. Acknowledgement
  31. Contents, Volume 45, 2007
  32. Author Index
  33. Subject Index
Downloaded on 6.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.339/html
Scroll to top button